Abstract
Fibroblast growth factor 23 (FGF23) gene is found to be responsible for autosomal dominant hypophosphatemic rickets, and is highly expressed in chronic kidney disease (CKD) and end-stage renal disease patients with iron deficiency anemia (IDA). We evaluated the efficacy of different iron treatments on FGF23 levels in dialysis-dependent and non-dialysis-dependent CKD patients with IDA. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing different types of iron treatment versus placebo in CKD patients up to May 2020. We investigated the efficacy of iron treatment on the levels of FGF23 and C-terminal FGF23 (cFGF23) in CKD patients. We estimated weighted mean differences (WMDs) and 95% confidence intervals (CIs) using the random-effects model. Nine studies with 11 arms were included in the meta-analysis. Overall, iron treatment showed a significant reduction in FGF23 levels compared to control group (WMD: − 60.56 pg/ml, 95% CI: − 92.17, − 28.95). Compared to placebo, subgroup analysis showed that oral iron therapy (WMD: − 6.98 pg/ml, 95% CI: − 10.66, − 3.31) was more effective than intravenous (IV) iron therapy (WMD: 4.90 pg/ml, 95% CI: − 12.03, 21.83) on FGF23 levels. There was no significant change in cFGF23 levels between iron treatment and control group (WMD: − 64.72 Ru/ml, 95% CI: − 147.69, 18.25). Subgroup analysis showed that oral iron therapy resulted in a significant reduction in cFGF23 levels compared to control group (WMD: − 150.48 RU/ml, 95% CI: − 151.31, − 149.65). In conclusion, iron treatment was associated with a significant decrease in FGF23 levels in CKD patients.
Similar content being viewed by others
References
Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB et al (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 39010105:1888–1917
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M et al (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 39510225:709–733
Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR (2020) Targeting the progression of chronic kidney disease. Nat Rev Nephrol 165:269–288
Fukumoto S. Chapter 63 - fibroblast growth factor 23. In: Bilezikian JP, Martin TJ, Clemens TL, Rosen CJ, editors. Principles of bone biology (fourth edition): Academic Press; 2020. p. 1529–38
Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV (2020) Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag 16:245–259
David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V et al (2016) Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 891:135–146
Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE et al (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 655:728–736
Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 288:1793–1803
Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M et al (2019) A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 308:1495–1504
Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K et al (2019) Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrology Dialysis Transplantation. 347:1115–1124
Honda H, Tanaka K, Michihata T, Shibagaki K, Yuza T, Hirao K et al (2019) Differential impacts of intravenous iron administration and iron-containing phosphate binders on serum intact fibroblast growth factor 23 levels. Blood Purif 472:63–69
Huang LL, Lee D, Troster SM, Kent AB, Roberts MA, Macdougall IC et al (2018) A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrology Dialysis Transplantation 339:1628–1635
Iguchi A, Yamamoto S, Yamazaki M, Tasaki K, Suzuki Y, Kazama JJ et al (2018) Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. Clin Exp Nephrol 224:789–796
Maruyama N, Otsuki T, Yoshida Y, Nagura C, Kitai M, Shibahara N et al (2018) Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients. Am J Nephrol 476:406–414
Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K et al (2019) Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 91:1–9
Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K et al (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 93:543–552
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 67:e1000097
RoB 2: A revised Cochrane risk-of-bias tool for randomized trials 2020 [updated 2020/12/29/. Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials
Jackson D, White IR, Thompson SG (2010) Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med 2912:1282–1297
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj. 3277414:557–560
Harre FE Jr, Lee KL, Pollock BG (1988) Regression models in clinical studies: determining relationships between predictors and response. JNCI: Journal of the National Cancer Institute 8015:1198–1202
Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj. 3157109:629–634
Begg CB (1994) Publication bias. The handbook of research synthesis 25:299–409
Tan S, Satake S, Smith E, Toussaint N, Hewitson T, Holt S (2017) Parenteral iron polymaltose changes i: c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. Eur J Clin Nutr 712:180–184
Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG (2009) FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. The Journal of Clinical Endocrinology & Metabolism 947:2332–2337
White KE, Hum JM, Econs MJ (2014) Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis. Current osteoporosis reports 123:252–262
Suresh K, Chandrashekara S (2012) Sample size estimation and power analysis for clinical research studies. Journal of Human Reproductive Sciences 51:7
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(DOCX 26 kb)
Rights and permissions
About this article
Cite this article
Abu-Zaid, A., Magzoub, D., Aldehami, M.A. et al. The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis. Biol Trace Elem Res 199, 4516–4524 (2021). https://doi.org/10.1007/s12011-021-02598-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12011-021-02598-1